We’re an agile health economics and outcomes consultancy that anticipates your needs and exceeds your expectations

Recent activities

Economic value of insertable cardiac monitors in unexplained syncope in the United States

We’re excited to have co-authored a publication in the BMJ Open Heart Journal assessing the cost-effectiveness of a novel diagnostic device. 

Interview with Anna Pagotto about NICE appraisals of immuno-oncology (I-O) drugs

We’re starting a new research project to  understand the factors that lead the National Institute of Care Excellence (NICE) in the UK to accept or reject I-O drug appraisals.

Assessing the quality and coherence of network meta-analyses of biologics in plaque psoriasis: what does all this evidence synthesis tell us?

We’re excited to have co-authored a publication in Dermatology and Therapy to appraise and synthesise the published evidence on biological therapies for plaque psoriasis. 

Our work in numbers

43

total clients

28

billion USD – average client turnover

67

% of work conducted with global HQ

Our story

We discover and drive innovative solutions to bring lifesaving treatments to patients around the world.

We work with our clients as a trusted partner and critical friend. Hence our name, Symmetron, from the Greek sym (together) and metron (calculate).

Since 2008, we have been growing steadily in size and capability into a highly-respected source of research in health economics and health outcomes.

Find out more about our successes 

We discover and drive innovative solutions to bring lifesaving treatments to patients around the world.

We work with our clients as a trusted partner and critical friend. Hence our name, Symmetron, from the Greek sym (together) and metron (calculate).

Since 2008, we have been growing steadily in size and capability to a highly-respected source of research in health economics and health outcomes.

Find out more about our successes